drugset / Trial / NCT03980041
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to measure the effect of IPI-549 in combination with nivolumab when compared to nivolumab monotherapy in advanced urothelial cancer patients.
Timeline
- Start
- 2019-09-25
- Primary completion
- 2020-11-30
- Completion
- 2022-11-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 480 mg | Intravenous |
| Subject | eganelisib | Small molecule | 40 mg | Oral |